2019 - AAI-Steinman Award for Human Immunology Research, American Association of Immunologists
2019 - Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR)
2018 - Albany Medical Center Prize in Medicine and Biomedical Research
2012 - Keio Medical Science Prize, Keio University, Tokyo, Japan
2010 - Karl Landsteiner Memorial Award, American Association of Blood Banks (AABB)
1987 - Member of the National Academy of Medicine (NAM)
Immunology, Immunotherapy, Antigen, Melanoma and Adoptive cell transfer are his primary areas of study. His research integrates issues of Cytotoxic T cell and Cancer research in his study of Immunology. His study on Immunotherapy is covered under Cancer.
His research in Antigen focuses on subjects like Molecular biology, which are connected to T-cell receptor. In his work, Gastroenterology and Surgery is strongly intertwined with Internal medicine, which is a subfield of Melanoma. His Interleukin 2 research focuses on Lymphokine-activated killer cell and how it connects with Cell culture.
His primary areas of investigation include Immunology, Immunotherapy, Antigen, Melanoma and Cancer research. As a part of the same scientific study, he usually deals with the Immunology, concentrating on Cytotoxic T cell and frequently concerns with CD8. His study in Immunotherapy is interdisciplinary in nature, drawing from both In vivo and Pathology.
Steven A. Rosenberg has researched Antigen in several fields, including Molecular biology, Antibody and T-cell receptor. His Melanoma study integrates concerns from other disciplines, such as Metastasis and Tumor antigen. The study incorporates disciplines such as Gastroenterology, Surgery and Cardiology in addition to Internal medicine.
His primary scientific interests are in Cancer research, Immunology, Adoptive cell transfer, Immunotherapy and Cancer. In his study, Mutant is inextricably linked to T cell, which falls within the broad field of Cancer research. He has included themes like Cell, Tumor-infiltrating lymphocytes, T-cell receptor, Minigene and Chimeric antigen receptor in his Adoptive cell transfer study.
His Immunotherapy research includes elements of Cytotoxic T cell and Lung cancer, Oncology. His Cancer research is included under the broader classification of Internal medicine. His Antigen study integrates concerns from other disciplines, such as Receptor, Immune system and Cancer immunotherapy.
Steven A. Rosenberg mainly focuses on Immunology, Immunotherapy, Antigen, Adoptive cell transfer and Cancer. His research links Cytotoxic T cell with Immunology. His research in Immunotherapy intersects with topics in Melanoma and Oncology.
His Antigen research is multidisciplinary, incorporating perspectives in Receptor, Cancer research, Cyclophosphamide and Somatic cell. His studies deal with areas such as Minigene, Cancer immunotherapy, MHC class I, T-cell receptor and Interleukin 2 as well as Adoptive cell transfer. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cancer : Principles and Practice of Oncology
Vincent T. DeVita;Samuel Hellman;Steven A. Rosenberg.
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Steven A. Rosenberg;Michael T. Lotze;Linda M. Muul;Alfred E. Chang.
The New England Journal of Medicine (1987)
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu.
The New England Journal of Medicine (2003)
Cancer immunotherapy: moving beyond current vaccines.
Steven A Rosenberg;James C Yang;Nicholas P Restifo.
Nature Medicine (2004)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang.
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
Steven A. Rosenberg;Michael T. Lotze;Linda M. Muul;Susan Leitman.
The New England Journal of Medicine (1985)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes.
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Elizabeth A Grimm;A. Mazumder;H. Z. Zhang;S. A. Rosenberg.
Journal of Experimental Medicine (1982)
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
S A Rosenberg;B S Packard;P M Aebersold;D Solomon.
The New England Journal of Medicine (1988)
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
Steven A. Rosenberg;Paul Spiess;Rene Lafreniere.
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: